Cancer – ADVL1412: Phase 1/2 Study of Nivolumab in Children, Adolescents and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
Condition or Therapy:
Sarcomas and solid tumors
Cancer and Blood Disorders
Study Number: ADVL1412
What is the goal of this study?
Researchers want to determine the best dosage of nivolumab when given with or without ipilimumab to determine how to treat patients with refractory or recurrent solid tumors or sarcomas.
Who can join the study?
This study may be a good fit for children and young adults who:
- are between 12 months and 30 years old, and
- have recurrent or refractory tumors including neuroblastoma, osteosarcoma, rhabdomysarcoma, Ewing sarcoma, Hodgkin lymphoma or non-Hodgkin lymphoma.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.